Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shenzhen Kangtai is a leading Chinese biopharmaceutical company specializing in the research, development, production, and sales of human vaccines. It has 11 products approved for market launch or emergency use—including the world’s first 60-microgram hepatitis B vaccine and China’s first four-dose human diploid cell rabies vaccine. The company operates five major R&D/industrial bases in China and maintains a broad product portfolio with significant international progress.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shenzhen Kangde.